Execs hail ‘merger of equals’ in Supernus, Indivior dealCiting structural synergies and a diversified portfolio, Supernus Pharmaceuticals Inc. and Indivior Pharmaceuticals Inc. are combining operations in a tax-free, all-stock merger. Upon close of the deal, expected in the fourth quarter of 2026, the combined firm will operate under the Supernus name and will boast a commercial portfolio of 11 CNS-targeting medicines, led by Indivior’s Sublocade (buprenorphine extended-release subcutaneous injection), a once-monthly treatment for opioid use disorder, which recorded sales of nearly $1 billion for the 12-month period ending June 30, 2026.